These scientific advances indicate the need to pursue a wider range of non-amyloid targets associated with aging and the underlying biology of Alzheimer's disease, such as inflammation, vascular dysfunction, aberrant proteostasis and autophagy, tau protein abnormalities, mitochondrial oxidative stress, metabolic dysfunction, cellular senescence, and epigenetic dysregulation [1,2,11]. The gene discussed is MAPT; the disease is Alzheimer disease.